Financial reports
10-Q
2024 Q3
Quarterly report
9 Aug 24
10-Q
2024 Q2
Quarterly report
10 May 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
10-Q
2024 Q1
Quarterly report
9 Feb 24
10-K
2023 FY
Annual report
15 Dec 23
10-Q
2023 Q3
Quarterly report
9 Aug 23
10-Q
2023 Q2
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
10-K/A
2022 FY
Annual report (amended)
27 Mar 23
10-Q
2023 Q1
Quarterly report
10 Feb 23
Current reports
8-K
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
9 Aug 24
8-K
Regulation FD Disclosure
24 Jun 24
8-K
Departure of Directors or Certain Officers
30 May 24
8-K
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
10 May 24
8-K
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
9 Feb 24
8-K
Edesa Biotech Reports Fiscal Year 2023 Results
15 Dec 23
8-K
Other Events
26 Oct 23
8-K
Entry into a Material Definitive Agreement
23 Oct 23
8-K
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
12 Oct 23
8-K
Edesa Biotech Announces One-for-Seven Reverse Share Split
11 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
31 May 24
S-8
Registration of securities for employees
24 May 23
424B5
Prospectus supplement for primary offering
27 Mar 23
424B3
Prospectus supplement
23 Dec 22
S-3
Shelf registration
16 Dec 22
S-3
Shelf registration
5 Aug 22
424B4
Prospectus supplement with pricing info
19 Apr 22
S-1
IPO registration
11 Apr 22
D
Indefinite amount in options / securities to be acquired, 1 investor
5 Apr 22
424B5
Prospectus supplement for primary offering
23 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
DEF 14A
Definitive proxy
28 Mar 23
DEF 14A
Definitive proxy
1 Apr 22
DEF 14A
Definitive proxy
3 Mar 21
DEFA14A
Additional proxy soliciting materials
24 Mar 20
DEF 14A
Definitive proxy
23 Mar 20
DEF 14C
Information statement
25 Oct 19
DEFA14A
Additional proxy soliciting materials
8 May 19
DEFM14A
Proxy related to merger
18 Apr 19
Other
EFFECT
Notice of effectiveness
27 Dec 22
CORRESP
Correspondence with SEC
21 Dec 22
UPLOAD
Letter from SEC
21 Dec 22
EFFECT
Notice of effectiveness
15 Aug 22
CORRESP
Correspondence with SEC
10 Aug 22
UPLOAD
Letter from SEC
9 Aug 22
EFFECT
Notice of effectiveness
20 Apr 22
CORRESP
Correspondence with SEC
15 Apr 22
UPLOAD
Letter from SEC
15 Apr 22
EFFECT
Notice of effectiveness
9 Mar 20
Ownership